Table 2.
Metabolic co-morbidities and medications in participants with healthy weight and with morbid obesity.
| Healthy weight | Morbid obesity | ||
|---|---|---|---|
| (n = 21) | Pre-surgery (n = 21) | Post-surgery (n = 17) | |
| Diabetes, n (%) | 0 | 6 (28.5) | 1 (5.9) |
| Metformin, n | 0 | 6 | 1 |
| Sulphonylurea, n | 0 | 3 | 0 |
| DPP-IV inhibitor, n | 0 | 2 | 0 |
| GLP-1 agonist, n | 0 | 0 | 0 |
| SGL2 inhibitor, n | 0 | 2 | 1 |
| Alpha-glucosidase inhibitor, n | 0 | 1 | 0 |
| 1 medication, n | 0 | 3 | 0 |
| 2 medications, n | 0 | 1 | 1 |
| 3 medications, n | 0 | 1 | 0 |
| ≥ 4 medications, n | 0 | 1 | 0 |
| Hypertension, n (%) | 10 (47.6) | 6 (35.3) | |
| Beta-blockers, n | 0 | 3 | 2 |
| ACE inhibitors/angiotensin II receptor blocker, n | 0 | 6 | 3 |
| Thiazide, n | 0 | 2 | 1 |
| Calcium channel blocker, n | 0 | 7 | 4 |
| 1 medication, n | 0 | 4 | 5 |
| 2 medications, n | 0 | 5 | 0 |
| ≥ 3 medications, n | 0 | 1 | 1 |
| Hyperlipidemia, n (%) | 7 (35) | 2 (11.8) | |
| Statins, n | 0 | 5 | 2 |
| Ezetimibe, n | 0 | 1 | 0 |
| Fibrates, n | 0 | 1 | 0 |
| 1 medication, n | 0 | 2 | 2 |
| 2 medications, n | 0 | 4 | 0 |
| 3 medications, n | 0 | 0 | 0 |